CN111433196B - 缓激肽b2受体拮抗剂及其用途 - Google Patents
缓激肽b2受体拮抗剂及其用途 Download PDFInfo
- Publication number
- CN111433196B CN111433196B CN201880076162.XA CN201880076162A CN111433196B CN 111433196 B CN111433196 B CN 111433196B CN 201880076162 A CN201880076162 A CN 201880076162A CN 111433196 B CN111433196 B CN 111433196B
- Authority
- CN
- China
- Prior art keywords
- methyl
- fluoro
- chloro
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203675.8 | 2017-11-24 | ||
| EP17203675 | 2017-11-24 | ||
| PCT/EP2018/082338 WO2019101906A1 (en) | 2017-11-24 | 2018-11-23 | Novel bradykinin b2 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111433196A CN111433196A (zh) | 2020-07-17 |
| CN111433196B true CN111433196B (zh) | 2023-06-06 |
Family
ID=60473364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880076162.XA Active CN111433196B (zh) | 2017-11-24 | 2018-11-23 | 缓激肽b2受体拮抗剂及其用途 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10836748B2 (enExample) |
| EP (2) | EP3713928B1 (enExample) |
| JP (2) | JP7164619B2 (enExample) |
| KR (1) | KR102413321B1 (enExample) |
| CN (1) | CN111433196B (enExample) |
| AR (1) | AR113839A1 (enExample) |
| AU (1) | AU2018371186B2 (enExample) |
| BR (1) | BR112020010298A2 (enExample) |
| CA (1) | CA3082948A1 (enExample) |
| CY (1) | CY1125348T1 (enExample) |
| DK (1) | DK3713928T3 (enExample) |
| EA (1) | EA202091256A1 (enExample) |
| ES (1) | ES2908409T3 (enExample) |
| HR (1) | HRP20220429T1 (enExample) |
| HU (1) | HUE058217T2 (enExample) |
| IL (1) | IL274883B2 (enExample) |
| LT (1) | LT3713928T (enExample) |
| MA (1) | MA50804B1 (enExample) |
| MX (1) | MX2020005287A (enExample) |
| PH (1) | PH12020550683A1 (enExample) |
| PL (1) | PL3713928T3 (enExample) |
| PT (1) | PT3713928T (enExample) |
| RS (1) | RS63087B1 (enExample) |
| SG (1) | SG11202004653TA (enExample) |
| SI (1) | SI3713928T1 (enExample) |
| SM (1) | SMT202200154T1 (enExample) |
| TW (1) | TWI768156B (enExample) |
| UY (1) | UY37981A (enExample) |
| WO (1) | WO2019101906A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3713928B1 (en) | 2017-11-24 | 2022-01-12 | Pharvaris Netherlands B.V. | Novel bradykinin b2 receptor antagonists |
| UY38706A (es) * | 2019-05-23 | 2020-12-31 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| AR118983A1 (es) * | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| MX2023005563A (es) * | 2020-11-12 | 2023-09-11 | Pharvaris Gmbh | Profilaxis y tratamiento del angioedema. |
| US20250145584A1 (en) | 2021-08-05 | 2025-05-08 | Pharvaris Gmbh | Solid form of a bradykinin b2-receptor antagonist |
| HRP20240525T1 (hr) * | 2021-08-05 | 2024-07-05 | Pharvaris Gmbh | Pripravak na bazi lipida za oralnu primjenu antagonista bradikininskog b2-receptora |
| US20250228781A1 (en) | 2022-03-25 | 2025-07-17 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
| WO2023180577A1 (en) | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Therapeutic uses of bradykinin b2-receptor antagonists |
| TW202345810A (zh) | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200843767A (en) * | 2007-03-23 | 2008-11-16 | Jerini Ag | Small molecule bradykinin B2 receptor modulators |
| EP2344477A1 (en) * | 2008-09-22 | 2011-07-20 | Jerini AG | Small molecule bradykinin b2 receptor modulators |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680870B2 (en) | 1993-04-28 | 1997-08-14 | Astellas Pharma Inc. | New heterocyclic compounds |
| EP0807105B1 (en) | 1994-10-27 | 2004-06-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE19612067A1 (de) | 1996-03-27 | 1997-10-02 | Hoechst Ag | Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| EP1085895A1 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Bradykinin antagonists |
| KR100419404B1 (ko) | 1998-10-21 | 2004-02-21 | 후지사와 야꾸힝 고교 가부시키가이샤 | 공지된 브라디키닌 길항제의 유리질 형태 |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| WO2001056995A1 (en) | 2000-01-18 | 2001-08-09 | Nuerogen Corporation | Substituted imidazoles as selective modulators of bradykinin b2 receptors |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| AU2003226188A1 (en) | 2002-04-10 | 2003-10-27 | Ortho-Mcneil Pharmaceutical, Inc. | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| EP1741444A1 (en) | 2005-07-05 | 2007-01-10 | Jerini AG | Kinin antagonists for treating bladder dysfunction |
| HK1220136A1 (zh) | 2013-03-14 | 2017-04-28 | Shire Human Genetic Therapies, Inc. | 治疗b2-缓激肽受体介导的血管性水肿的方法 |
| EP3713928B1 (en) | 2017-11-24 | 2022-01-12 | Pharvaris Netherlands B.V. | Novel bradykinin b2 receptor antagonists |
-
2018
- 2018-11-23 EP EP18818992.2A patent/EP3713928B1/en active Active
- 2018-11-23 ES ES18818992T patent/ES2908409T3/es active Active
- 2018-11-23 JP JP2020545875A patent/JP7164619B2/ja active Active
- 2018-11-23 SG SG11202004653TA patent/SG11202004653TA/en unknown
- 2018-11-23 PT PT188189922T patent/PT3713928T/pt unknown
- 2018-11-23 PL PL18818992T patent/PL3713928T3/pl unknown
- 2018-11-23 KR KR1020207017972A patent/KR102413321B1/ko active Active
- 2018-11-23 UY UY0001037981A patent/UY37981A/es active IP Right Grant
- 2018-11-23 LT LTEPPCT/EP2018/082338T patent/LT3713928T/lt unknown
- 2018-11-23 BR BR112020010298-9A patent/BR112020010298A2/pt active IP Right Grant
- 2018-11-23 IL IL274883A patent/IL274883B2/en unknown
- 2018-11-23 HU HUE18818992A patent/HUE058217T2/hu unknown
- 2018-11-23 EP EP21213719.4A patent/EP3998259A1/en active Pending
- 2018-11-23 MA MA50804A patent/MA50804B1/fr unknown
- 2018-11-23 CA CA3082948A patent/CA3082948A1/en active Pending
- 2018-11-23 CN CN201880076162.XA patent/CN111433196B/zh active Active
- 2018-11-23 SM SM20220154T patent/SMT202200154T1/it unknown
- 2018-11-23 AR ARP180103444A patent/AR113839A1/es unknown
- 2018-11-23 TW TW107141872A patent/TWI768156B/zh active
- 2018-11-23 WO PCT/EP2018/082338 patent/WO2019101906A1/en not_active Ceased
- 2018-11-23 AU AU2018371186A patent/AU2018371186B2/en active Active
- 2018-11-23 HR HRP20220429TT patent/HRP20220429T1/hr unknown
- 2018-11-23 SI SI201830628T patent/SI3713928T1/sl unknown
- 2018-11-23 MX MX2020005287A patent/MX2020005287A/es unknown
- 2018-11-23 EA EA202091256A patent/EA202091256A1/ru unknown
- 2018-11-23 RS RS20220335A patent/RS63087B1/sr unknown
- 2018-11-23 DK DK18818992.2T patent/DK3713928T3/da active
-
2020
- 2020-04-28 US US16/861,131 patent/US10836748B2/en active Active
- 2020-05-21 PH PH12020550683A patent/PH12020550683A1/en unknown
- 2020-09-25 US US17/033,347 patent/US11261173B2/en active Active
-
2022
- 2022-01-18 US US17/578,161 patent/US11820756B2/en active Active
- 2022-04-11 CY CY20221100272T patent/CY1125348T1/el unknown
- 2022-10-20 JP JP2022168473A patent/JP2023002701A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200843767A (en) * | 2007-03-23 | 2008-11-16 | Jerini Ag | Small molecule bradykinin B2 receptor modulators |
| EP2344477A1 (en) * | 2008-09-22 | 2011-07-20 | Jerini AG | Small molecule bradykinin b2 receptor modulators |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111433196B (zh) | 缓激肽b2受体拮抗剂及其用途 | |
| CN113906020B (zh) | 环状缓激肽b2受体拮抗剂 | |
| CN113906018B (zh) | 缓激肽b2受体拮抗剂 | |
| HK40031700B (en) | Novel bradykinin b2 receptor antagonists | |
| HK40031700A (en) | Novel bradykinin b2 receptor antagonists | |
| EA043330B1 (ru) | Новые антагонисты рецептора брадикинина | |
| HK40068438A (en) | (r)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (bk) b2 receptor antagonist for treating skin diseases | |
| HK40068438B (en) | (r)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (bk) b2 receptor antagonist for treating skin diseases | |
| HK40068437A (en) | 1-((s)-1-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)ethyl)-imidazolidine-2,4-dione derivatives and related compounds as bradykinin (bk) b2 receptor antagonist for treating skin diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |